In conclusion, these results indicate that Sorafenib not only protects against RIPK1/3-dependent cell death in vitro, but also against RIPK1/3-dependent lethality in TNF-induced SIRS. The gene discussed is RIPK1; the disease is systemic inflammatory response syndrome.